1 / 10

Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test

Lutz Pichl , DRK-Blutspendedienst West Christine Jork, DRK-Blutspendedienst NSTOB. Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test. Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion Service West, Hagen, Germany.

elda
Download Presentation

Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lutz Pichl , DRK-Blutspendedienst West Christine Jork, DRK-Blutspendedienst NSTOB Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar SchottstedtGerman Red Cross Blood Transfusion Service West, Hagen, Germany

  2. ~ 4,000 - 6,000 samples/ day Hagen

  3. cobas s 201 system

  4. evaluation of the Roche cobas s 201 System in combination with the TaqScreen MPX test feasibility to screen plasma minipools(pools size  96 samples) for HCV, HIV-1,HIV-1 O, HIV-2 and HBVby multiplex PCR in a large blood bank setting Aim of the study

  5. Fully automated, IVD-conf. , CE-marked system Focus on the performance of the MPX test rather than on hardware features of the s 201(lab sample pooling unit and PCR unit with CAP/CTM systems have been operated since 2005 under routine screening conditions)minipools are processed by the integrated Hamilton Microlab Star pipettor like single units Conditions

  6. 16 high titre, positive donor samples (5 HBV-DNA pos., 5 HCV-DNA pos., 5 HIV-1 pos.) and 16 non-reactive donor samples in alternating manner of 32 position on 2 racks titres HBV: 8.0 EE8, HCV: 1.0 EE7, HIV-1: 1.0 EE6 2 different loading schemes were analysed result: no cross-contamination observed except 1 false (weak-) positive HCV (Ct 46.3 vs. Ct 18.4) Cross-Contamination Study

  7. Reproducibility • 3 Run Controls: HBV: 30 IU/ml HCV: 50 IU/ml HIV-1: 160 IU/ml • 8 replicates of each control were analysed on 4 daysby 2 operators with 2 different kit lots

  8. Haemolysed plasma samples consisted of up to 20% (v/v) lysed red cell concentrate (12,550 mg/dl Hb) lipaemic plasma samples (871 mg/dl triglycerides) “green colored” plasma from female donors under hormonal treatment Individual plasma samples were seperately spiked with HBV (30 IU/ml), HIV-1M (50 IU/ml) and HCV (160 IU/ml),final concentrations 5 (haemolytic) to 20 replicates (lipaemic/ green) were analysed  Induced high concentrations of hemoglobin, fat and other possibly interfering substances showed no inhibitory effect on PCR results at definite concentrations. Potential interference with endogenous substances

  9. NIBSC HCV RNA genotype panel 02/202 for NAT,final conc. 100 IU/ml  all panel members detected Acrometrix VQC PeliCheck HBV-DNA genotype panel (1,000 cop/ml)  all panel members detected NIBSC 1st Int. Ref. Panel 01/466 for HIV-1 RNA  all panel members detected except for HIV 01-466 (group O)  further investigation Genotype Inclusivity

  10. Screening minipools (n =96) from blood donations

More Related